Zealand Pharma A/S (OTCMKTS:ZLDPF) Shares Up 9.1% – Here’s Why

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) shot up 9.1% during mid-day trading on Monday . The stock traded as high as $44.71 and last traded at $44.71. 500 shares were traded during mid-day trading, a decline of 90% from the average session volume of 4,843 shares. The stock had previously closed at $40.99.

Analyst Upgrades and Downgrades

ZLDPF has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. BNP Paribas Exane cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 6th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a report on Friday, March 6th. Three analysts have rated the stock with a Strong Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Zealand Pharma A/S Price Performance

The business has a 50-day moving average of $56.07 and a 200 day moving average of $67.96. The company has a current ratio of 23.57, a quick ratio of 23.57 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $3.18 billion, a P/E ratio of 3.27 and a beta of 0.76.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings data on Thursday, February 19th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.34) by $0.53. Zealand Pharma A/S had a return on equity of 48.10% and a net margin of 70.06%.The firm had revenue of $10.79 million during the quarter, compared to the consensus estimate of $19.69 million. On average, sell-side analysts predict that Zealand Pharma A/S will post -2.19 earnings per share for the current fiscal year.

About Zealand Pharma A/S

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.